Miriam Komaromy, MD is the Medical Director of the Grayken Center for Addiction at Boston Medical Center, and a Professor in the Division of General Internal Medicine, Department of Medicine, Boston University School of Medicine. In her role at the Grayken Center she leads programs focused on expanding access to care and engagement with care for patients who have substance use disorders, particularly those from marginalized patient populations. Other areas of focus within the Grayken Center include:
--Development of a new Grayken Addiction Nursing Fellowship and support for the Grayken Addiction Medicine Fellowships
--Leadership on adaptation of SUD treatment during the COVID pandemic, including BMC's COVID Recuperation Unit for people who are COVID-infected and experiencing homelessness
--Research focused on care of young adults with substance use disorder and on care of BIPOC populations
--Policy and Advocacy focused on workforce development, harm reduction, HIV prevention, and overdose prevention in newly housed individuals
Komaromy is also PI of a NIMH-funded clinical trial (along with mPI Dr. Kate Watkins of RAND corporation) that is evaluating the impact of the Collaborative Care model on outcomes of care for people who have co-occurring opioid use disorder plus PTSD or depression in 13 primary care clinics in New Mexico.
Prior to her role at BMC, Komaromy led the Extension for Healthcare Outcomes (ECHO) Institute’s programs for addiction and psychiatry. She has also served on the American Society of Addiction Medicine’s (ASAM’s) National Board of Directors (2017-2021) and served as medical director for a state addiction treatment hospital in New Mexico and for Albuquerque Health Care for the Homeless.
Komaromy recently partnered with the American Society of Addiction Medicine to launch an ECHO hub to educate health care professionals around the country on the treatment of substance use disorders. She also led the federally-funded program that developed and launched five national ECHO hubs focused on treatment of opioid use disorder (including one based in BMC's OBAT program), after developing the nation’s first addiction-focused ECHO program.
Komaromy was previously a professor in the Department of Internal Medicine at the University of New Mexico. She received her medical degree from the University of California, San Francisco and completed her residency in internal medicine at UCSF/San Francisco General Hospital. She was a Robert Wood Johnson Clinical Scholar at the UCSF/Stanford program. She joined the UCSF faculty of Medicine after her training, and served as the residency director for the UCSF Primary Care Internal Medicine Residency program at San Francisco General Hospital. She is board certified in Addiction Medicine by the American Board of Preventive Medicine.
Komaromy’s research has focused on health disparities and care for traditionally underserved populations; models of post-graduate medical education; and care for patients with substance use disorders and complex health conditions. In 2018, Komaromy received a Fulbright Scholar award from the US State Department, teaching about substance use disorders and medical education in Vietnam, Thailand, and Indonesia and studying treatment of opioid use disorder in Vietnam. She is the vice-chair of the ASAM National Medical Education Committee. In 2019 she received ASAM's Educator of the Year award.
2019 Psychiatric Services Journal:
Editor's Choice Award
Educator of the Year
2018 US State Department:
Fulbright Scholar, Hanoi Vietnam
Awarded “Distinguished Fellow”
2016 Association for Medical Education and Research in Substance Abuse:
Best program/ Curriculum Abstract
2016 Substance Abuse Journal:
Article of the Year Award
2014 Physician Support Service:
National Mentor for Medication Assisted Treatment
2013 American College of Physicians:
2010 Bernalillo County Commission:
Exceptional Public Service Award
2008 Physician Support Service:
National Mentor for Buprenorphine Treatment
1996 Association of Health Services Research:
Article of the Year Award
Outstanding Intern of the Year Award
Alpha Omega Alpha
Improving Access and Treatment for Co-occurring Opioid Use Disorders and Mental Illness
09/12/2019 - 09/30/2021 (PI)
RAND Corporation NIH-NIMH
COVID Recuperation Unit White Paper - NoA issued 07/22/20-
08/03/2020 - 10/23/2020 (PI)
Grant to develop curriculum focused on substance use disorders
09/01/2019 - 09/01/2021 (PI)
Grant to develop a white paper on how to develop and implement a medical recuperation facility for COVID-infected people experiencing homelessness.
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 38 results.
Laks J, Kehoe J, Farrell NM, Komaromy M, Kolodziej J, Walley AY, Taylor JL. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule. Addict Sci Clin Pract. 2021 Dec 28; 16(1):73.View Related Profiles. PMID: 34961554; PMCID: PMC8712102; DOI: 10.1186/s13722-021-00279-x;
Komaromy M, Tomanovich M, Taylor JL, Ruiz-Mercado G, Kimmel SD, Bagley SM, Saia KM, Costello E, Park TW, LaBelle C, Weinstein Z, Walley AY. Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic. J Addict Med. 2021 Nov-Dec 01; 15(6):448-451.View Related Profiles. PMID: 33298750; PMCID: PMC8562917; DOI: 10.1097/ADM.0000000000000791;
Qeadan F, Azagba S, Barbeau WA, Gu LY, Mensah NA, Komaromy M, English K, Madden EF. Associations between discrimination and substance use among college students in the United States from 2015 to 2019. Addict Behav. 2022 Feb; 125:107164. PMID: 34735979
Harris MTH, Young S, Barocas J, Bayoumi AM, Caudarella A, Laurence G, Tomanovich M, Komaromy M. A Descriptive Comparison of Substance Use Services in Recovery and Isolation Sites for People Experiencing Homelessness During the COVID-19 Pandemic, Boston and Toronto. Public Health Rep. 2021 Sep-Oct; 136(5):532-537.View Related Profiles. PMID: 34269625; PMCID: PMC8361564; DOI: 10.1177/00333549211032974;
Meredith LS, Komaromy MS, Cefalu M, Murray-Krezan C, Page K, Osilla KC, Dopp AR, Leamon I, Tarhuni L, Hindmarch G, Jacobsohn V, Watkins KE. Design of CLARO (Collaboration Leading to Addiction Treatment and Recovery from other Stresses): A randomized trial of collaborative care for opioid use disorder and co-occurring depression and/or posttraumatic stress disorder. Contemp Clin Trials. 2021 05; 104:106354. PMID: 33713840; PMCID: PMC8432760; DOI: 10.1016/j.cct.2021.106354;
Komaromy M, Mendez-Escobar E, Madden E. Addressing Racial Trauma in the Treatment of Substance Use Disorders. Pediatrics. 2021 01; 147(Suppl 2):S268-S270. PMID: 33386331
Barocas JA, Komaromy M, Haidar D, Barlam TF, Orr BL, Miller NS. Assessment of Oropharyngeal Specimens for Discontinuation of Transmission-Based COVID-19 Precautions. Open Forum Infect Dis. 2020 Sep; 7(9):ofaa382.View Related Profiles. PMID: 32964067; PMCID: PMC7494181; DOI: 10.1093/ofid/ofaa382;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
Available to Mentor as: (Review Mentor Role Definitions)
I enjoy mentorship and have mentored many researchers and educators at my own and other institutions. I particularly enjoy cross-disciplinary mentorship roles. I am available to provide work/life integration mentorship, and support around parenting, particulary to LGBTQ faculty. Please contact me at Miriam.Komaromy@bmc.org
Research / Scholarly Mentor
Work / Life Integration Mentor